<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120493</url>
  </required_header>
  <id_info>
    <org_study_id>CT-AMT-130-01</org_study_id>
    <nct_id>NCT04120493</nct_id>
  </id_info>
  <brief_title>Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease</brief_title>
  <official_title>A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UniQure Biopharma B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UniQure Biopharma B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first study of AMT-130 in patients with early manifest HD and is designed to&#xD;
      establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase I/II, randomized,&#xD;
      multicenter, dose escalation, double-blind, imitation surgery, first-in-human (FIH) study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMT-130 is an investigational, single administration gene therapy intended to modify the&#xD;
      disease course for HD. Preclinical studies have shown that AMT-130 lowers huntingtin protein&#xD;
      and is associated with decreased progression of Huntington disease signs in animal models.&#xD;
&#xD;
      This 5-year trial consists of a blinded 12-month Core Study Period to evaluate the safety and&#xD;
      potential impact of AMT-130 on disease progression and an unblinded 4-year Long-Term Period&#xD;
      with periodic follow-up visits to evaluate the safety of AMT-130 and disease progression in&#xD;
      treated individuals. Following completion of the 12-month blinded post treatment follow-up&#xD;
      period, subjects will be individually unblinded. Once the crossover has been activated after&#xD;
      review of data by the DSMB and FDA, subjects randomized to the imitation (sham) procedure who&#xD;
      continue to meet inclusion/exclusion criteria (including adequate MRI striatal volumes) will&#xD;
      be allowed to crossover to receive AMT-130 treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2019</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and type of Adverse Events (AE)</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be assessed by adverse events (AEs) related to clinical safety laboratory tests, vital signs, electrocardiograms (ECGs), neurological and physical examinations, rAAV5 vector shedding, immunogenicity response, suicidality risk [Columbia-Suicide Severity Rating Scale [C-SSRS)], changes in global cognitive functioning [Montreal Cognitive Assessment Scale (MoCA)] and MRI measures of edema, inflammation, volume loss and structural changes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of persistence of AMT-130 in the brain</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>Change over time in levels of AMT-130-derived Vector DNA and miRNA Expression in the Cerebrospinal Fluid (CSF)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CSF Mutant Protein (fM)</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>CSF/Serum Neurofilament Light Chain (pg/mL)</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Unified Huntington Disease Rating Scale (UHDRS)</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>The UHDRS will assess changes from baseline in summary scores of domains of motor function, cognitive function, behavioral function, and functional abilities.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative Motor (Q-Motor) Testing</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>Q-Motor testing will measure disease progression and responsiveness to AMT-130 treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Huntington's Disease Cognitive Assessment Battery (HD-CAB)</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>The HD-CAB measures cognitive dysfunction in late premanifest and early manifest HD patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>MRI assessments will include whole brain volume, striatal region volumes, white matter volume, gray matter volume, ventricular volume, cortical thickness, and diffusion MRI measures.</description>
  </other_outcome>
  <other_outcome>
    <measure>Magnetic Resonance Spectroscopy (MRS)</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>MRS will be collected using single-voxel point resolved spectroscopy of the left putamen and white matter region immediately adjacent to the left putamen. Neuronal health and gliosis will be evaluated by measuring total N-acetylaspartic acid (neuronal integrity marker) and myoinisitol (reactive astrocytosis marker) levels.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neuro-QoL Measures</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>The Neuro-QoL is a brief, reliable, valid, standardized set of patient reported, Health Related Quality of Life (HRQoL) measures for people living with neurological conditions.</description>
  </other_outcome>
  <other_outcome>
    <measure>HDQLIFE Measures</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>The HDQLIFE is a measurement system that was designed to provide a brief, reliable and valid assessment of HRQoL in HD and consists of NeuroQoL measures that have been validated in the HD population and several new HD specific measures.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Collected for duration of study through month 60</time_frame>
    <description>The HADS is a 14-item, self-report measure that has been shown to be reliable and valid for identifying depression and anxiety in adults who are physically ill. Each item is scored from 0 (no anxiety or depression) to 3 (abnormal anxiety or depression) for a maximum total score of 21.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose rAAV5-miHTT (6x10^12 gc/subject).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose rAAV5-miHTT (6x10^13 gc/subject).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohorts 1 and 2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Imitation (sham) surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>intra-striatal rAAV5-miHTT</intervention_name>
    <description>One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>AMT-130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imitation (sham) surgery</intervention_name>
    <description>Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull</description>
    <arm_group_label>Cohorts 1 and 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Early manifest HD as defined by a UHDRS total functional capacity (TFC) score of 9 to&#xD;
             13 and EITHER a diagnostic classification level (DCL) of 4 OR a DCL of 3 if the&#xD;
             subject either meets the definition of multidimensional manifest HD (UHDRS question&#xD;
             80) or has cognitive symptoms&#xD;
&#xD;
          -  HTT gene expansion testing with the presence of ≥40 CAG repeats.&#xD;
&#xD;
          -  Striatal MRI volume requirements per hemisphere: Putamen ≥2.5 cm3 (per side); Caudate&#xD;
             ≥2.0 cm3 (per side)&#xD;
&#xD;
          -  All HD concomitant medications (addressing motor, behavioral, and cognitive symptoms)&#xD;
             stable for 3 months prior to Screening.&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
          -  Able and willing to comply with all procedures and study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of suicide risk&#xD;
&#xD;
          -  Receipt of an experimental agent within 60 days or five half-lives prior to Screening&#xD;
             or anytime over the duration of this study.&#xD;
&#xD;
          -  Participation in an investigational trial or investigational paradigm (such as&#xD;
             exercise/physical activity, cognitive therapy, brain stimulation, etc.) within 60 days&#xD;
             prior to Screening or anytime over the duration of this study.&#xD;
&#xD;
          -  Presence of an implanted deep brain stimulation device, ventriculoperitoneal or other&#xD;
             CSF shunt, or other implanted catheter&#xD;
&#xD;
          -  Any history of gene therapy, RNA or DNA targeted HD specific investigational agents,&#xD;
             such as antisense oligonucleotides (ASO), cell transplantation or any other&#xD;
             experimental brain surgery.&#xD;
&#xD;
          -  Any contraindication to lumbar puncture or 3.0 Tesla MRI as per local guidelines.&#xD;
&#xD;
          -  Brain and spinal pathology that may interfere with the surgical delivery of AMT-130 or&#xD;
             represents a significant neurologic comorbid disorder.&#xD;
&#xD;
          -  Hospitalization for any major medical or surgical procedure involving general&#xD;
             anesthesia within 12 weeks of Screening or planned during the study.&#xD;
&#xD;
          -  Current or recurrent disease, infection, or other significant concurrent medical&#xD;
             condition or medications that could confound clinical and laboratory evaluations or&#xD;
             could affect a subject's safety or their ability to undergo the neurosurgical&#xD;
             procedure or comply with the procedures and study visit schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cooper, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniQure Biopharma B.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Lopez, MS</last_name>
    <phone>781-777-3697</phone>
    <email>amt130_clinical_trials@uniqure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Smith</last_name>
      <phone>205-996-2807</phone>
      <email>jltidwell@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Sung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Glueck</last_name>
      <phone>415-502-7640</phone>
      <email>julia.glueck@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Geschwind, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyle Rizer</last_name>
      <phone>352-733-2426</phone>
      <email>kyle.rizer@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Nikolaus McFarland, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Hawkins</last_name>
      <phone>312-563-5563</phone>
      <email>Jacob_Hawkins@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Hall, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kia Ultz</last_name>
      <phone>410-955-1349</phone>
      <email>kcarte23@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mollie Webb Jenckes</last_name>
      <email>mjenckes@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Ross, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Sierra</last_name>
      <email>lsierra1@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Frank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Department of Neurology</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Stovall</last_name>
      <phone>734-647-4787</phone>
      <email>astovall@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Praveen Dayalu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Ambrogi</last_name>
      <phone>614-688-6685</phone>
      <email>Katherine.Ambrogi@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sandra Kostyk, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Buchanan</last_name>
      <phone>615-875-3274</phone>
      <email>danielle.a.buchanan@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Claassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Sims</last_name>
      <phone>713-500-7763</phone>
      <email>Jamie.Sims@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Furr-Stimming, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University VCU School of Medicine, Department of Neurology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather L Ward</last_name>
      <phone>804-382-0076</phone>
      <email>heather.ward@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Barrett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Del Castillo</last_name>
      <phone>206-543-3647</phone>
      <email>debradel@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Ali Samii, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene therapy</keyword>
  <keyword>AAV (adeno-associated virus)</keyword>
  <keyword>serotype 5 AAV (adeno-associated virus)</keyword>
  <keyword>serotype 5</keyword>
  <keyword>Viral vector</keyword>
  <keyword>miHTT</keyword>
  <keyword>muHTT</keyword>
  <keyword>Huntington Disease (HD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

